South San Francisco
California, United States of America
We have an exciting opportunity for a highly motivated Postdoctoral Fellow to join the Antibody Engineering department at Genentech. The successful postdoctoral candidate will focus their research on understanding novel conformational and post-translationally modified states of proteins of therapeutic interest, with an emphasis on developing, characterizing, and applying conformation-specific antibodies. While several targets of high interest have been identified, the opportunity to drive new projects and technology also exists. The successful postdoctoral candidate will work closely with a highly collaborative group of scientists whose expertise includes antibody engineering, X-ray crystallography, and cryo-electron microscopy (cryo-EM).
This postdoctoral scientist will be responsible for the discovery of novel conformational antibodies and/or antibodies against novel post translational modifications and subsequent biophysical and structural characterization. The individual will also work with collaborators in Oncology and Immunology to apply these novel reagents to study cell signaling. A proven track-record in optimizing the expression and purification of challenging proteins is highly desirable. Proficiency in X-ray crystallography and/or cryo-EM methods is strongly preferred.
Required qualifications: Ph.D. in biochemistry, biophysics, bioengineering, and/or structural biology with strong experience in protein biochemistry. Productive doctoral training is expected and should be reflected through a record of high-impact publications.
Additional recommended qualifications:
This postdoc position will be co-mentored by JT Koerber and Sarah Hymowitz
For information about the Genentech Postdoctoral Program, visit:
Liau N et al, Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3 induced dimerization. Nat. Struct. Mol Biol, in press.
Storek KM et al. Massive antibody discovery used to probe structure-function relationships of the essential outer membrane protein LptD. Elife 2019.
Haling JR et al., Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell. 2014 Sep 8;26(3):402-413.
Koerber JT et al. Nature-inspired design of motif-specific antibodies. Nature Biotechnology 2013.
A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 40 years, using human genetic information to develop novel medicines for serious and life-threatening diseases. Genentech has multiple therapies on the market for cancer & other serious illnesses. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
The next step is yours. To apply today, click on the "Apply online" button.
Genentech is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. For more information about equal employment opportunity, visit our Genentech Careers page.
These are our stories - stories of the obstacles and opportunities that define and celebrate the unique people at Genentech.